186 related articles for article (PubMed ID: 36369791)
1. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
3. LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression.
Cao X; Zhang G; Li T; Zhou C; Bai L; Zhao J; Tursun T
Genes Genomics; 2020 Nov; 42(11):1361-1368. PubMed ID: 32996041
[TBL] [Abstract][Full Text] [Related]
4. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.
Xia P; Zhang H; Lu H; Xu K; Jiang X; Jiang Y; Gongye X; Chen Z; Liu J; Chen X; Ma W; Zhang Z; Yuan Y
Cancer Commun (Lond); 2023 Mar; 43(3):338-364. PubMed ID: 36602428
[TBL] [Abstract][Full Text] [Related]
5. Silencing of RAB42 down-regulated PD-L1 expression to inhibit the immune escape of hepatocellular carcinoma cells through inhibiting the E2F signaling pathway.
Kong J; Wang X; Wang J; Yu G
Cell Signal; 2023 Aug; 108():110692. PubMed ID: 37116555
[TBL] [Abstract][Full Text] [Related]
6. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
7. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
8. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
[TBL] [Abstract][Full Text] [Related]
9. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
[TBL] [Abstract][Full Text] [Related]
10. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
11. CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.
Zhong X; Kan A; Zhang W; Zhou J; Zhang H; Chen J; Tang S
Aging (Albany NY); 2019 Aug; 11(15):5483-5497. PubMed ID: 31375643
[TBL] [Abstract][Full Text] [Related]
12. CBX3 regulated by miR-139 promotes the development of HCC by regulating cell cycle progression.
Zhang P; Yang X; Zha Z; Zhu Y; Zhang G; Li G
Cell Cycle; 2022 Aug; 21(16):1740-1752. PubMed ID: 35471148
[TBL] [Abstract][Full Text] [Related]
13. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
14. The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression.
Wang Q; Huang Y; Zhu Y; Zhang W; Wang B; Du X; Dai Q; Zhang F; Fang Z
Cancer Med; 2024 Apr; 13(7):e7165. PubMed ID: 38613157
[TBL] [Abstract][Full Text] [Related]
15. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.
Zhang X; Pan B; Qiu J; Ke X; Shen S; Wang X; Tang N
Int J Exp Pathol; 2022 Jun; 103(3):102-111. PubMed ID: 35429078
[TBL] [Abstract][Full Text] [Related]
16. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis.
Zeng C; Ye S; Chen Y; Zhang Q; Luo Y; Gai L; Luo B
J Immunol Res; 2021; 2021():9289719. PubMed ID: 34988230
[TBL] [Abstract][Full Text] [Related]
17. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
18. microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2.
Dai HT; Wang ST; Chen B; Tang KY; Li N; Wen CY; Wan Y; Zhang GY; Huang YH; Geng ZJ
Neoplasma; 2022 Jan; 69(1):16-27. PubMed ID: 34818025
[TBL] [Abstract][Full Text] [Related]
19. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Liu J; Liu Y; Meng L; Liu K; Ji B
Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]